Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL

A 36-month analysis of a phase i and II study

Kensuke Usuki, Arinobu Tojo, Yasuhiro Maeda, Yukio Kobayashi, Akira Matsuda, Kazuma Ohyashiki, Chiaki Nakaseko, Tatsuya Kawaguchi, Hideo Tanaka, Tadashi Nagai, Yasushi Miyazaki, Shinichiro Okamoto, Taro Amagasaki, Kenji Oritani, Aira Wanajo, Masaya Okada, Tomoki Naoe, Koichi Miyamura, Noriko Usui

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Although the tyrosine kinase inhibitor (TKI) imatinib is often used as first-line therapy for newly diagnosed chronic myelogenous leukemia (CML), some patients fail to respond, or become intolerant to imatinib. Nilotinib is a potent and selective second-generation TKI, with confirmed efficacy and tolerability in patients with imatinib-resistant or -intolerant CML. A phase I/II study was conducted in Japanese patients with imatinib-resistant or -intolerant CML or relapsed/refractory Phfl acute lymphoblastic leukemia. Thirty-four patients were treated with nilotinib for up to 36 months. Major cytogenetic response was achieved in 15/16 patients (93.8%) with chronic-phase CML within a median of approximately 3 months. Major molecular response was achieved in 13/16 patients (81.3%). These responses were sustained at the time of the most recent evaluation in 13 patients and 11 patients, respectively. Hematologic and cytogenetic responses were also observed in patients with advanced CML. The BCR-ABL mutation associated with the most resistance to available TKIs, T315I, was observed in three patients. Common adverse events included rash, nasopharyngitis, leukopenia, neutropenia, thrombocytopenia, nausea, headache and vomiting. Most adverse events resolved following nilotinib dose interruptions/reductions. These results support the favorable longterm efficacy and tolerability of nilotinib in Japanese patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia.

Original languageEnglish
Pages (from-to)409-419
Number of pages11
JournalInternational Journal of Hematology
Volume95
Issue number4
DOIs
Publication statusPublished - 2012 Apr

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Safety
Leukemia, Myeloid, Chronic Phase
Cytogenetics
Protein-Tyrosine Kinases
Imatinib Mesylate
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Nasopharyngitis
Leukopenia
Exanthema
Neutropenia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Thrombocytopenia
Nausea
Vomiting
Headache
Mutation

Keywords

  • Acute lymphoblastic leukemia
  • Chronic myeloid leukemia
  • Nilotinib
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology

Cite this

Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL : A 36-month analysis of a phase i and II study. / Usuki, Kensuke; Tojo, Arinobu; Maeda, Yasuhiro; Kobayashi, Yukio; Matsuda, Akira; Ohyashiki, Kazuma; Nakaseko, Chiaki; Kawaguchi, Tatsuya; Tanaka, Hideo; Nagai, Tadashi; Miyazaki, Yasushi; Okamoto, Shinichiro; Amagasaki, Taro; Oritani, Kenji; Wanajo, Aira; Okada, Masaya; Naoe, Tomoki; Miyamura, Koichi; Usui, Noriko.

In: International Journal of Hematology, Vol. 95, No. 4, 04.2012, p. 409-419.

Research output: Contribution to journalArticle

Usuki, K, Tojo, A, Maeda, Y, Kobayashi, Y, Matsuda, A, Ohyashiki, K, Nakaseko, C, Kawaguchi, T, Tanaka, H, Nagai, T, Miyazaki, Y, Okamoto, S, Amagasaki, T, Oritani, K, Wanajo, A, Okada, M, Naoe, T, Miyamura, K & Usui, N 2012, 'Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: A 36-month analysis of a phase i and II study', International Journal of Hematology, vol. 95, no. 4, pp. 409-419. https://doi.org/10.1007/s12185-012-1026-9
Usuki, Kensuke ; Tojo, Arinobu ; Maeda, Yasuhiro ; Kobayashi, Yukio ; Matsuda, Akira ; Ohyashiki, Kazuma ; Nakaseko, Chiaki ; Kawaguchi, Tatsuya ; Tanaka, Hideo ; Nagai, Tadashi ; Miyazaki, Yasushi ; Okamoto, Shinichiro ; Amagasaki, Taro ; Oritani, Kenji ; Wanajo, Aira ; Okada, Masaya ; Naoe, Tomoki ; Miyamura, Koichi ; Usui, Noriko. / Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL : A 36-month analysis of a phase i and II study. In: International Journal of Hematology. 2012 ; Vol. 95, No. 4. pp. 409-419.
@article{a73761dcb5a54a2bbee4c90d10b3160c,
title = "Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: A 36-month analysis of a phase i and II study",
abstract = "Although the tyrosine kinase inhibitor (TKI) imatinib is often used as first-line therapy for newly diagnosed chronic myelogenous leukemia (CML), some patients fail to respond, or become intolerant to imatinib. Nilotinib is a potent and selective second-generation TKI, with confirmed efficacy and tolerability in patients with imatinib-resistant or -intolerant CML. A phase I/II study was conducted in Japanese patients with imatinib-resistant or -intolerant CML or relapsed/refractory Phfl acute lymphoblastic leukemia. Thirty-four patients were treated with nilotinib for up to 36 months. Major cytogenetic response was achieved in 15/16 patients (93.8{\%}) with chronic-phase CML within a median of approximately 3 months. Major molecular response was achieved in 13/16 patients (81.3{\%}). These responses were sustained at the time of the most recent evaluation in 13 patients and 11 patients, respectively. Hematologic and cytogenetic responses were also observed in patients with advanced CML. The BCR-ABL mutation associated with the most resistance to available TKIs, T315I, was observed in three patients. Common adverse events included rash, nasopharyngitis, leukopenia, neutropenia, thrombocytopenia, nausea, headache and vomiting. Most adverse events resolved following nilotinib dose interruptions/reductions. These results support the favorable longterm efficacy and tolerability of nilotinib in Japanese patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia.",
keywords = "Acute lymphoblastic leukemia, Chronic myeloid leukemia, Nilotinib, Tyrosine kinase inhibitors",
author = "Kensuke Usuki and Arinobu Tojo and Yasuhiro Maeda and Yukio Kobayashi and Akira Matsuda and Kazuma Ohyashiki and Chiaki Nakaseko and Tatsuya Kawaguchi and Hideo Tanaka and Tadashi Nagai and Yasushi Miyazaki and Shinichiro Okamoto and Taro Amagasaki and Kenji Oritani and Aira Wanajo and Masaya Okada and Tomoki Naoe and Koichi Miyamura and Noriko Usui",
year = "2012",
month = "4",
doi = "10.1007/s12185-012-1026-9",
language = "English",
volume = "95",
pages = "409--419",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL

T2 - A 36-month analysis of a phase i and II study

AU - Usuki, Kensuke

AU - Tojo, Arinobu

AU - Maeda, Yasuhiro

AU - Kobayashi, Yukio

AU - Matsuda, Akira

AU - Ohyashiki, Kazuma

AU - Nakaseko, Chiaki

AU - Kawaguchi, Tatsuya

AU - Tanaka, Hideo

AU - Nagai, Tadashi

AU - Miyazaki, Yasushi

AU - Okamoto, Shinichiro

AU - Amagasaki, Taro

AU - Oritani, Kenji

AU - Wanajo, Aira

AU - Okada, Masaya

AU - Naoe, Tomoki

AU - Miyamura, Koichi

AU - Usui, Noriko

PY - 2012/4

Y1 - 2012/4

N2 - Although the tyrosine kinase inhibitor (TKI) imatinib is often used as first-line therapy for newly diagnosed chronic myelogenous leukemia (CML), some patients fail to respond, or become intolerant to imatinib. Nilotinib is a potent and selective second-generation TKI, with confirmed efficacy and tolerability in patients with imatinib-resistant or -intolerant CML. A phase I/II study was conducted in Japanese patients with imatinib-resistant or -intolerant CML or relapsed/refractory Phfl acute lymphoblastic leukemia. Thirty-four patients were treated with nilotinib for up to 36 months. Major cytogenetic response was achieved in 15/16 patients (93.8%) with chronic-phase CML within a median of approximately 3 months. Major molecular response was achieved in 13/16 patients (81.3%). These responses were sustained at the time of the most recent evaluation in 13 patients and 11 patients, respectively. Hematologic and cytogenetic responses were also observed in patients with advanced CML. The BCR-ABL mutation associated with the most resistance to available TKIs, T315I, was observed in three patients. Common adverse events included rash, nasopharyngitis, leukopenia, neutropenia, thrombocytopenia, nausea, headache and vomiting. Most adverse events resolved following nilotinib dose interruptions/reductions. These results support the favorable longterm efficacy and tolerability of nilotinib in Japanese patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia.

AB - Although the tyrosine kinase inhibitor (TKI) imatinib is often used as first-line therapy for newly diagnosed chronic myelogenous leukemia (CML), some patients fail to respond, or become intolerant to imatinib. Nilotinib is a potent and selective second-generation TKI, with confirmed efficacy and tolerability in patients with imatinib-resistant or -intolerant CML. A phase I/II study was conducted in Japanese patients with imatinib-resistant or -intolerant CML or relapsed/refractory Phfl acute lymphoblastic leukemia. Thirty-four patients were treated with nilotinib for up to 36 months. Major cytogenetic response was achieved in 15/16 patients (93.8%) with chronic-phase CML within a median of approximately 3 months. Major molecular response was achieved in 13/16 patients (81.3%). These responses were sustained at the time of the most recent evaluation in 13 patients and 11 patients, respectively. Hematologic and cytogenetic responses were also observed in patients with advanced CML. The BCR-ABL mutation associated with the most resistance to available TKIs, T315I, was observed in three patients. Common adverse events included rash, nasopharyngitis, leukopenia, neutropenia, thrombocytopenia, nausea, headache and vomiting. Most adverse events resolved following nilotinib dose interruptions/reductions. These results support the favorable longterm efficacy and tolerability of nilotinib in Japanese patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia.

KW - Acute lymphoblastic leukemia

KW - Chronic myeloid leukemia

KW - Nilotinib

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84862835151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862835151&partnerID=8YFLogxK

U2 - 10.1007/s12185-012-1026-9

DO - 10.1007/s12185-012-1026-9

M3 - Article

VL - 95

SP - 409

EP - 419

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 4

ER -